Expanded Access for AG-221

Celgene

Status

Conditions: Acute Myeloid Leukemia

Treatments: Drug: AG-221

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03723057

AG-221

Details and patient eligibility

About

This is an expanded access program (EAP) for eligible participants designed to provide access to AG-221.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Exclusion criteria